AbbVie amps up 'armed antibody' deal with Seattle Genetics to the tune of $255M

Whatever AbbVie ($ABBV) learned in the first stages of its collaboration with Seattle Genetics ($SGEN) on antibody-drug conjugates must have seriously whetted the pharma company's appetite. AbbVie is now paying $25 million upfront and up to $255 million more in milestones for each new target they tackle in a greatly expanded partnership. Report